The cell engineering technology leader AVECTAS launched the Solupore platform at the Advanced Therapies Week in Miami Beach Convention Centre on January 16th 2023.

Solupore clinical manufacturing system for non-viral delivery to enable next- generation cell therapies.
Solupore clinical manufacturing system for non-viral delivery to enable next-generation cell therapies. (Photo by Avectas)

The Solupore non-viral delivery system enables the clinical manufacturing of advanced cell therapies differentiated by unparalleled cell health and superior cell functionality. This novel system expands the possibilities for complex editing and challenging cargo delivery. Solupore technology works by temporarily permeabilizing the target cell membrane so that molecular cargoes such as mRNA, plasmids, RNP or CRISPR/Cas9 can be delivered while retaining superior cell health and function.

Avectas has developed an extensive data package based on primary T cells that includes performance in complex editing, cell health characterization, in vitro and in vivo functional performance. Avectas is expanding this dataset to include other cell types, including induced pluripotent stem cells (iPSCs).

Several partners have accessed the technology under an early access program, including Genscript, Inceptor Bio, and CCRM/Omnia bio.

“I am proud that our brilliant team is launching Solupore today after focused development over several years. I believe Solupore is poised to address the limitations of current transfection technologies for modifying therapeutic cells. Our system will seamlessly integrate into GMP processes to manufacture healthy and highly functional cells. Launching our clinical manufacturing system brings us closer to fulfilling our vision of working with partners to accelerate the future of cell therapies for patients.”

Michael Maguire, PhD, CEO of Avectas